{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T21:53:38Z","timestamp":1785880418336,"version":"3.56.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004853","name":"Chinese University of Hong Kong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004853","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003808","name":"Hospital Authority","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003808","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eclinm.2025.103712","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T07:34:54Z","timestamp":1766129694000},"page":"103712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Comparing rosuvastatin and atorvastatin on cardiovascular and kidney outcomes in patients with diabetes across chronic kidney disease stages: an emulated target trial in China"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-6297-5418","authenticated-orcid":false,"given":"Yanting","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2193-1114","authenticated-orcid":false,"given":"Hongjiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calvin","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana NM.","family":"Lui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8927-6764","authenticated-orcid":false,"given":"Alice PS.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald CW.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jones","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond SM.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6717-5444","authenticated-orcid":false,"given":"Brian","family":"Tomlinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea OY.","family":"Luk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana CN.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4147-3387","authenticated-orcid":false,"given":"Elaine","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.eclinm.2025.103712_bib1","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic kidney disease: challenges, progress, and possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6865","key":"10.1016\/j.eclinm.2025.103712_bib2","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/414782a","article-title":"Global and societal implications of the diabetes epidemic","volume":"414","author":"Zimmet","year":"2001","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103712_bib3","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103712_bib4","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts","volume":"79","author":"van der Velde","year":"2011","journal-title":"Kidney Int"},{"issue":"4s","key":"10.1016\/j.eclinm.2025.103712_bib5","first-page":"S117","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103712_bib6","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jacc.2010.01.020","volume":"55","author":"Ridker","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103712_bib7","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1053\/j.ajkd.2008.11.025","article-title":"Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD","volume":"53","author":"Koren","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"21","key":"10.1016\/j.eclinm.2025.103712_bib8","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1161\/CIR.0000000000000456","article-title":"Recommendations for management of clinically significant drug-drug interactions with statins and select agents used in patients with cardiovascular disease: a scientific statement from the American heart Association","volume":"134","author":"Wiggins","year":"2016","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103712_bib9","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1681\/ASN.2022020135","article-title":"Association of rosuvastatin use with risk of hematuria and proteinuria","volume":"33","author":"Shin","year":"2022","journal-title":"J Am Soc Nephrol"},{"issue":"23","key":"10.1016\/j.eclinm.2025.103712_bib10","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1161\/CIRCULATIONAHA.105.555482","article-title":"The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis","volume":"111","author":"Alsheikh-Ali","year":"2005","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103712_bib11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S2213-8587(14)70246-3","article-title":"Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial","volume":"3","author":"de Zeeuw","year":"2015","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eclinm.2025.103712_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-075837","article-title":"Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial","volume":"383","author":"Lee","year":"2023","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103712_bib13","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.7326\/M24-0178","article-title":"Comparative effectiveness and safety of atorvastatin versus rosuvastatin","volume":"177","author":"Zhou","year":"2024","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103712_bib14","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1185\/03007990802312807","article-title":"Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia","volume":"24","author":"Tzeng","year":"2008","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103712_bib15","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00228-014-1800-0","article-title":"Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States","volume":"71","author":"Birmingham","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103712_bib16","first-page":"1394","article-title":"National technical guidelines for the prevention and treatment of diabetic kidney disease in primary care (2023)]","volume":"62","year":"2023","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103712_bib17","first-page":"184","article-title":"The maximum dose of atorvastatin and simvastatin as well as rosuvastatin should be restricted in East Asians","volume":"30","author":"Tomlinson","year":"2024","journal-title":"Hong Kong Med J"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103712_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00228-014-1801-z","article-title":"Impact of ABCG2 and SLCO1B1 polymorphisms on pharmacokinetics of rosuvastatin, atorvastatin and simvastatin acid in Caucasian and Asian subjects: a class effect?","volume":"71","author":"Birmingham","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103712_bib19","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/cpt.1998","article-title":"A microdose cocktail to evaluate drug interactions in patients with renal impairment","volume":"109","author":"Tatosian","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.eclinm.2025.103712_bib20","series-title":"The US Food and Drug Administration: highlights of prescribing information for Crestor (rosuvastatin calcium) tablets","year":"2022"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103712_bib21","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1111\/dme.13014","article-title":"Quality of care in patients with diabetic kidney disease in Asia: the Joint Asia Diabetes Evaluation (JADE) registry","volume":"33","author":"Luk","year":"2016","journal-title":"Diabet Med"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103712_bib22","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103712_bib23","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1001\/jama.2025.13350","article-title":"Transparent reporting of observational studies emulating a target trial-the TARGET statement","volume":"334","author":"Cashin","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.eclinm.2025.103712_bib24","article-title":"The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103712_bib25","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1093\/ije\/dyab252","article-title":"Data resource profile: the Hong Kong Diabetes Surveillance Database (HKDSD)","volume":"51","author":"Wu","year":"2022","journal-title":"Int J Epidemiol"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103712_bib26","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s11892-023-01508-0","article-title":"Team-based diabetes care in Ontario and Hong Kong: a comparative review","volume":"23","author":"Ke","year":"2023","journal-title":"Curr Diab Rep"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103712_bib27","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.2337\/dci19-0003","article-title":"From Hong Kong Diabetes Register to JADE Program to RAMP-DM for data-driven actions","volume":"42","author":"Chan","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eclinm.2025.103712_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102568","article-title":"Clinical outcomes following discontinuation of metformin in patients with type 2 diabetes and advanced chronic kidney disease in Hong Kong: a territory-wide, retrospective cohort and target trial emulation study","volume":"71","author":"Yang","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103712_bib29","doi-asserted-by":"crossref","first-page":"2967","DOI":"10.2337\/dc20-0260","article-title":"Trends in glucose-lowering drug use, glycemic control, and severe hypoglycemia in adults with diabetes in Hong Kong, 2002-2016","volume":"43","author":"Yang","year":"2020","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103712_bib30","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1007\/s00125-021-05452-0","article-title":"Long-term metformin use and risk of pneumonia and related death in type 2 diabetes: a registry-based cohort study","volume":"64","author":"Yang","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.eclinm.2025.103712_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101751","article-title":"Clinical outcomes following discontinuation of renin-angiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: a prospective cohort study","volume":"55","author":"Yang","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.eclinm.2025.103712_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.110203","article-title":"Initiation of sodium-glucose cotransporter-2 inhibitors at lower HbA1c threshold attenuates eGFR decline in type 2 diabetes patients with and without cardiorenal disease: a propensity-matched cohort study","volume":"195","author":"Cheung","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103712_bib33","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"23","key":"10.1016\/j.eclinm.2025.103712_bib34","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity Score method that mimics attributes of a randomized clinical trial","volume":"323","author":"Thomas","year":"2020","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103712_bib35","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/pds.2074","article-title":"The role of the c-statistic in variable selection for propensity score models","volume":"20","author":"Westreich","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103712_bib36","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/ckj\/sfaa024","article-title":"An introduction to joint models-applications in nephrology","volume":"13","author":"Chesnaye","year":"2020","journal-title":"Clin Kidney J"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103712_bib37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/pds.4372","article-title":"Methods for time-varying exposure related problems in pharmacoepidemiology: an overview","volume":"27","author":"Pazzagli","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103712_bib38","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hern\u00e1n","year":"2000","journal-title":"Epidemiology"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103712_bib39","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","article-title":"Negative controls: a tool for detecting confounding and bias in observational studies","volume":"21","author":"Lipsitch","year":"2010","journal-title":"Epidemiology"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103712_bib40","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/cpt.2980","article-title":"Understanding statin-roxadustat drug-drug-disease interaction using physiologically-based pharmacokinetic modeling","volume":"114","author":"Dong","year":"2023","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103712_bib41","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1093\/ndt\/gfy159","article-title":"Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials","volume":"34","author":"Idzerda","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103712_bib42","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1185\/030079907X242809","article-title":"A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)","volume":"23","author":"Zhu","year":"2007","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103712_bib43","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1253\/circj.CJ-11-1385","article-title":"Effects of rosuvastatin and atorvastatin on renal function: meta-analysis","volume":"76","author":"Wu","year":"2012","journal-title":"Circ J"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103712_bib44","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1253\/circj.CJ-10-1281","article-title":"Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial","volume":"75","author":"Saku","year":"2011","journal-title":"Circ J"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103712_bib46","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04371206","article-title":"Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study","volume":"2","author":"Shepherd","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103712_bib47","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1177\/1074248407306676","article-title":"Dose-dependent effect of rosuvastatin treatment on urinary protein excretion","volume":"12","author":"Kostapanos","year":"2007","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103712_bib48","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1517\/14740338.3.6.547","article-title":"Rosuvastatin safety: lessons from the FDA review and post-approval surveillance","volume":"3","author":"Davidson","year":"2004","journal-title":"Expert Opin Drug Saf"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103712_bib49","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1097\/01.ASN.0000136778.32499.05","article-title":"Inhibitors of HMG-CoA reductase reduce receptor-mediated endocytosis in human kidney proximal tubular cells","volume":"15","author":"Verhulst","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103712_bib50","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1097\/01.ASN.0000138236.82706.EE","article-title":"Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells","volume":"15","author":"Sidaway","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103712_bib51","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1159\/000100908","article-title":"Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program","volume":"107","author":"Shepherd","year":"2007","journal-title":"Cardiology"},{"key":"10.1016\/j.eclinm.2025.103712_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1478697","article-title":"Tubulointerstitial injury in proteinuric chronic kidney diseases","volume":"11","author":"Cortinovis","year":"2024","journal-title":"Front Med"},{"key":"10.1016\/j.eclinm.2025.103712_bib53","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ahj.2018.12.007","article-title":"Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: a systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants","volume":"210","author":"Yebyo","year":"2019","journal-title":"Am Heart J"},{"issue":"24","key":"10.1016\/j.eclinm.2025.103712_bib54","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/eurheartj\/eht084","article-title":"Factors underlying regression of coronary atheroma with potent statin therapy","volume":"34","author":"Puri","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.eclinm.2025.103712_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-067731","article-title":"Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis","volume":"376","author":"Hodkinson","year":"2022","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103712_bib56","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s00059-018-4767-2","article-title":"Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol : a meta-analysis of trials with East Asian populations","volume":"45","author":"Zhang","year":"2020","journal-title":"Herz"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103712_bib57","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1080\/03007995.2017.1371584","article-title":"Efficacy and safety of rosuvastatin versus atorvastatin in high-risk Chinese patients with hypercholesterolemia: a randomized, double-blind, active-controlled study","volume":"34","author":"Zhao","year":"2018","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103712_bib58","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3390\/ph16040507","article-title":"Effects of statin dose, class, and use intensity on all-cause mortality in patients with type 2 diabetes mellitus","volume":"16","author":"Yu","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"23 Suppl 1","key":"10.1016\/j.eclinm.2025.103712_bib59","first-page":"Iii39","article-title":"Beneficial cardiovascular pleiotropic effects of statins","volume":"109","author":"Davignon","year":"2004","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103712_bib60","article-title":"Statin safety in Chinese: a population-based study of older adults","volume":"11","author":"Li","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103712_bib61","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/ejhpharm-2023-003765","article-title":"Rosuvastatin-induced rhabdomyolysis: case report and call for proactive multifactorial risk assessment and preventive management of statin therapy in high-risk patients","volume":"31","author":"Niedrig","year":"2024","journal-title":"Eur J Hosp Pharm"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103712_bib62","first-page":"474","article-title":"Cluster of cases of high-dose rosuvastatin-associated rhabdomyolysis and recent reduction of rosuvastatin dose for Asians in other countries","volume":"29","author":"Tse","year":"2023","journal-title":"Hong Kong Med J"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103712_bib63","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.amjmed.2014.03.018","article-title":"Premature mortality and comorbidities in young-onset diabetes: a 7-year prospective analysis","volume":"127","author":"Chan","year":"2014","journal-title":"Am J Med"},{"key":"10.1016\/j.eclinm.2025.103712_bib64","article-title":"Glucose-lowering drug use, glycemic outcomes, and severe hypoglycemia: 18-year trends in 0\u00b79 million adults with diabetes in Hong Kong (2002-2019)","volume":"26","author":"Yang","year":"2022","journal-title":"Lancet Reg Health West Pac"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006467?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025006467?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T11:23:56Z","timestamp":1777634636000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025006467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":63,"alternative-id":["S2589537025006467"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103712","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparing rosuvastatin and atorvastatin on cardiovascular and kidney outcomes in patients with diabetes across chronic kidney disease stages: an emulated target trial in China","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103712"}}